<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700267</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3970-CL-102</org_study_id>
    <secondary_id>2020-001820-32</secondary_id>
    <nct_id>NCT04700267</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus</brief_title>
  <acronym>TAPINOMA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus&#xD;
      (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK)&#xD;
      profile, safety and tolerability, and pharmacodynamics (PD) biomarkers related to the&#xD;
      investigational product (IP) mechanism of action and the pathophysiology of SLE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped on business grounds&#xD;
  </why_stopped>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Actual">October 6, 2021</completion_date>
  <primary_completion_date type="Actual">October 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in biomarkers associated with disease anti-dsDNA</measure>
    <time_frame>Between Day 1 and 104</time_frame>
    <description>To characterize the PD of GLPG3970 compared to placebo in adult subjects with active SLE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in biomarkers associated with disease complement component 3 (C3), and complement component 4 (C4)</measure>
    <time_frame>Between Day 1 and 104</time_frame>
    <description>To characterize the PD of GLPG3970 compared to placebo in adult subjects with active SLE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number, incidence, and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From screening through study completion, an average of 5 months</time_frame>
    <description>To evaluate the safety and tolerability of GLPG3970 compared to placebo in adult subjects with active SLE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed GLPG3970 plasma trough concentrations (Ctrough)</measure>
    <time_frame>Between Day 1 and 87</time_frame>
    <description>To characterize the PK of GLPG3970 in adult subjects with active SLE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>GLPG3970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose level of GLPG3970</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One dose level of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3970 film-coated tablet</intervention_name>
    <description>GLPG3970 for oral administration</description>
    <arm_group_label>GLPG3970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo film-coated tablet</intervention_name>
    <description>Placebo for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SLE diagnosis defined by American College of Rheumatology (ACR) 1997 criteria ≥4&#xD;
&#xD;
          -  Active arthritis in &gt;=4 active joints (according to 28 joint count) and/or cutaneous&#xD;
             lupus erythematosus disease area and severity index (CLASI) score &gt;=6.&#xD;
&#xD;
          -  Anti-dsDNA antibodies &gt;15 IU/mL.&#xD;
&#xD;
          -  Stable standard-of-care (SoC) therapy (defined as no change in prescription for at&#xD;
             least 2 weeks prior to first IP dosing) consisting of the following permitted SoC&#xD;
             medications:&#xD;
&#xD;
               -  Corticosteroids &lt;=20 mg/day (prednisone or equivalent) for at least 2 weeks prior&#xD;
                  to first IP dosing; AND/OR&#xD;
&#xD;
               -  Non-steroidal anti-inflammatory drug (NSAIDs); AND/OR&#xD;
&#xD;
               -  One single antimalarial at a stable dose (hydroxychloroquine &lt;=5 mg/ kg/day,&#xD;
                  quinacrine 100 mg/day, or chloroquine 2.3 mg/kg/day) for at least 8 weeks prior&#xD;
                  to first IP dosing; AND/OR&#xD;
&#xD;
               -  One single immunosuppressant at a stable dose (azathioprine (AZA) &lt;=2 mg/kg/day,&#xD;
                  methotrexate (MTX) &lt;=20 mg/week, or mycophenolate mofetil (MMF) &lt;=2 g/day) for at&#xD;
                  least 8 weeks prior to first IP dosing.&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) &gt;=60 mL/min (according to Chronic Kidney&#xD;
             Disease Epidemiology Collaboration (CKD-EPI))&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lupus nephritis &gt;= Class III&#xD;
&#xD;
          -  Severe organ manifestation or life-threatening lupus disease (active severe central&#xD;
             nervous system lupus, severe pleuro-pericarditis, severe vasculitis).&#xD;
&#xD;
          -  Severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection &gt;0&#xD;
&#xD;
          -  Unstable condition not related to SLE&#xD;
&#xD;
          -  Systemic inflammatory condition other than SLE such as, but not limited to rheumatoid&#xD;
             arthritis (RA), spondyloarthropathy, Crohn's disease, ulcerative colitis, or psoriatic&#xD;
             arthritis&#xD;
&#xD;
          -  Sjögren's syndrome and/or antiphospholipid antibody syndrome who do not require&#xD;
             treatment with any prohibited medication are NOT excluded.&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Poorly controlled chronic cardiac, pulmonary, or renal disease.&#xD;
&#xD;
          -  Known or suspected history of or a current immunosuppressive condition, or a history&#xD;
             of invasive opportunistic infections&#xD;
&#xD;
          -  Treatment with disallowed therapies&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Vincent, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical center Medconsult Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT-Plovdiv AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Phase I Unit</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im.dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Kraków</city>
        <zip>30363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureMeds sp. Z o. o.</name>
      <address>
        <city>Wrocław</city>
        <zip>50088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Ltd Liability Comp</name>
      <address>
        <city>Kyiv</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multidisciplinary Medical Center of Odesa National Medical University</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.I.Pirogov Vinnytsia Reg Council</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21028</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRI of Invalid Rehabilitation</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Suchasna klinika</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

